Latest Operating Expenses News

ReNerve Limited delivered its strongest sales quarter ever with $211,000 in revenue, boosted by new distribution deals in Asia-Pacific and a $5 million funding facility to underpin growth.

AdAlta has completed a key US$1 million milestone payment securing rights to its lead CAR-T therapy EW-001 outside Greater China, progressed Australian manufacturing with first runs expected late 2026, and is preparing for a critical pre-IND meeting with the US FDA.

Mach7 Technologies delivered a positive operating cash flow in Q4 FY26, boosted its ARR run rate by 7.6% in constant currency, and secured multi-year subscription deals while expanding its partner ecosystem.

Saluda Medical capped FY26 with a 28% revenue surge, beating guidance at US$90.2 million, while FDA approval for its CAP24 paddle lead opens a new US surgical market segment.

InteliCare generated positive cash flow for the first time since listing in the June 2026 quarter, driven by accelerated deployments across aged care and retirement living sectors.

Elixinol Wellness posted a record quarterly revenue of $4.3 million in Q2 FY26, driven by The Healthy Chef's expansion and a 45% gross margin. Cost cuts helped deliver positive underlying operating cash flow for the third straight quarter despite some one-off expenses.

Iluka Resources reported a rebound in zircon sales and prices in Q2 2026, while advancing its Eneabba rare earths refinery to nearly 60% completion and securing a key rare earths offtake deal.

Way2VAT Ltd lifted its Q2 FY26 revenue by 30%, launching the Way2Invoice e-invoicing platform amid growing global VAT compliance demands. The company also expanded its debt facility to support growth and pursue M&A opportunities.

Biome Australia (ASX: BIO) edged close to breakeven in FY26, driven by $1.8 million in international sales across four markets and a 68% gross margin. The company is set to launch onshore manufacturing and a digital health platform to accelerate growth.

AML3D Limited closed FY26 with a record $29 million order book, driven by US defence contracts and a $12 million investment to double its Ohio manufacturing capacity. The company’s cash receipts rose 20% to $10.4 million, while its sales pipeline expanded to $78 million.

Firebrick Pharma expanded its patent portfolio with grants in Canada and New Zealand while achieving 43% sales growth in FY26 despite steady operating expenses. The company is advancing Nasodine's commercial rollout across Southeast Asia and the US.

Metals X reported a steady tin output at Renison with a 5.9% tin price lift boosting revenue and EBITDA despite increased costs and a marginal net cash flow dip. Capital projects and exploration advanced, while the company’s strong cash reserves underpin its growth ambitions.